Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke

Area of Science:

• Neuroscience
• Pharmacology
• Emergency Medicine

Background:

• Tissue plasminogen activator (tPA) is the sole FDA-approved treatment for acute ischemic stroke.
• tPA therapy has limitations, including a narrow therapeutic window (3-6 hours) and increased risk of intracerebral hemorrhage (ICH).
• Free radicals are implicated in ischemic stroke progression and neurodegeneration, suggesting a role for scavengers in treatment.

Purpose of the Study:

• To evaluate the potential of novel spin trap agents, specifically NXY-059, as neuroprotective therapeutics for acute ischemic stroke.
• To investigate NXY-059's safety profile and its efficacy as an adjunct therapy to tPA.

Main Methods:

• Preclinical studies were conducted to assess the neuroprotective effects of NXY-059.
• Research focused on NXY-059's mechanism as a broad-spectrum nitrone-based free radical scavenger.
• Investigated NXY-059's impact on the therapeutic window and ICH incidence when used with tPA.

Main Results:

• NXY-059 demonstrated neuroprotective effects in preclinical models of ischemic stroke.
• The agent was found to be a broad-spectrum free radical scavenger with a favorable safety profile in humans.
• NXY-059 was shown to extend the therapeutic window for tPA and reduce the incidence of tPA-induced ICH in preclinical studies.

Conclusions:

• NXY-059 presents a promising therapeutic candidate for acute ischemic stroke.
• Its potential as an adjunct to tPA therapy warrants further investigation due to improved efficacy and safety outcomes.
• NXY-059 may offer a valuable new treatment option for stroke patients, addressing key limitations of current therapies.